MDT

89.45

+0.06%↑

VEEV

281.75

+1.73%↑

A

114.01

-1.72%↓

WBA

11.49

-0.17%↓

HQY

97.62

-1.48%↓

MDT

89.45

+0.06%↑

VEEV

281.75

+1.73%↑

A

114.01

-1.72%↓

WBA

11.49

-0.17%↓

HQY

97.62

-1.48%↓

MDT

89.45

+0.06%↑

VEEV

281.75

+1.73%↑

A

114.01

-1.72%↓

WBA

11.49

-0.17%↓

HQY

97.62

-1.48%↓

MDT

89.45

+0.06%↑

VEEV

281.75

+1.73%↑

A

114.01

-1.72%↓

WBA

11.49

-0.17%↓

HQY

97.62

-1.48%↓

MDT

89.45

+0.06%↑

VEEV

281.75

+1.73%↑

A

114.01

-1.72%↓

WBA

11.49

-0.17%↓

HQY

97.62

-1.48%↓

Search

Aurinia Pharmaceuticals Inc

Ouvert

SecteurSoins de santé

8.74 -2.35

Résumé

Variation du prix de l'action

24h

Actuel

Min

8.71

Max

9.07

Chiffres clés

By Trading Economics

Revenu

22M

23M

Ventes

2.6M

62M

P/E

Moyenne du Secteur

33.482

39.857

Marge bénéficiaire

37.371

Employés

130

EBITDA

15M

22M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+10.17% upside

Dividendes

By Dow Jones

Prochains Résultats

31 juil. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

93M

1.2B

Ouverture précédente

11.09

Clôture précédente

8.74

Sentiment de l'Actualité

By Acuity

34%

66%

108 / 376 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bullish Evidence

Aurinia Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

17 juil. 2025, 23:34 UTC

Acquisitions, Fusions, Rachats

FTC Reopens Consent Orders for Proposed Acquisitions from Exxon Mobil, Chevron

17 juil. 2025, 21:14 UTC

Acquisitions, Fusions, Rachats

Basel Medical Group Puts $1 Billion Bitcoin Purchase on Hold

17 juil. 2025, 21:04 UTC

Principaux Mouvements du Marché
Acquisitions, Fusions, Rachats

Norfolk Southern Shares Rise on WSJ Report of Union Pacific Acquisition Interest

17 juil. 2025, 23:43 UTC

Market Talk

Gold Edges Higher on Possible Position Adjustments -- Market Talk

17 juil. 2025, 23:42 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Econ Strength -- Market Talk

17 juil. 2025, 22:47 UTC

Acquisitions, Fusions, Rachats

FTC: Maintaining Restrictions for Former Pioneer CEO Scott Sheffield Would Damage FTC's Credibility

17 juil. 2025, 22:46 UTC

Acquisitions, Fusions, Rachats

Potential Rail Merger Could Prompt Berkshire Hathaway to Bid for CSX -- Barrons.com

17 juil. 2025, 22:46 UTC

Acquisitions, Fusions, Rachats

FTC Also Says Exxon Order Disregarded Guidelines and Precedent

17 juil. 2025, 22:43 UTC

Acquisitions, Fusions, Rachats

FTC: Maintaining Restrictions on John Hess's Employment Would 'Damage the FTC's Credibility'

17 juil. 2025, 22:43 UTC

Acquisitions, Fusions, Rachats

FTC: Chevron Order Disregarded FTC Merger Guidelines and Decades of Precedent

17 juil. 2025, 22:40 UTC

Acquisitions, Fusions, Rachats

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 juil. 2025, 22:40 UTC

Acquisitions, Fusions, Rachats

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 juil. 2025, 22:30 UTC

Market Talk
Résultats

Netflix Sticks to Its Playbook as Competitive Landscape Changes -- Market Talk

17 juil. 2025, 22:20 UTC

Market Talk
Résultats

Global Equities Roundup: Market Talk

17 juil. 2025, 22:20 UTC

Market Talk
Résultats

Netflix Focusing Resources on TV Viewers It Hasn't Yet Captured -- Market Talk

17 juil. 2025, 22:04 UTC

Market Talk
Résultats

Netflix Redesign Done to Match Current Capabilities -- Market Talk

17 juil. 2025, 22:03 UTC

Acquisitions, Fusions, Rachats

China Threatens to Block Panama Ports Deal Unless Its Shipping Giant Is Part of It -- 2nd Update

17 juil. 2025, 21:58 UTC

Market Talk
Résultats

Netflix Internal Data Doesn't Indicate Weaker Consumer Sentiment -- Market Talk

17 juil. 2025, 21:57 UTC

Résultats

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 juil. 2025, 21:47 UTC

Résultats

Netflix Raises Revenue, Margin Forecasts After Strong Second Quarter -- Update

17 juil. 2025, 21:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 juil. 2025, 21:45 UTC

Market Talk

Crypto Bills Welcomed by Venture Capital, Trade Group Says -- Market Talk

17 juil. 2025, 21:38 UTC

Acquisitions, Fusions, Rachats

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- 2nd Update

17 juil. 2025, 21:22 UTC

Acquisitions, Fusions, Rachats

Update: Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 juil. 2025, 21:05 UTC

Résultats

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 juil. 2025, 21:04 UTC

Acquisitions, Fusions, Rachats

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- Update

17 juil. 2025, 21:02 UTC

Acquisitions, Fusions, Rachats

Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 juil. 2025, 20:59 UTC

Acquisitions, Fusions, Rachats

Basel Medical Group Puts $1B Bitcoin Purchase on Hold

17 juil. 2025, 20:50 UTC

Market Talk
Résultats

Tech, Media & Telecom Roundup: Market Talk

17 juil. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Comparaison

Variation de prix

Aurinia Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

10.17% hausse

Prévisions sur 12 Mois

Moyen 9.75 USD  10.17%

Haut 11 USD

Bas 8 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

4

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

8.1 / 8.21Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Bullish Evidence

Sentiment

By Acuity

108 / 376Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.